Discover
BCAX
Bicara Therapeutics Inc. Common Stock
28.15
1 x 27.71
1 x 29.12
bid
ask
+
1.00
3.68%
04:00 PM
| Ytd | 67.26% | |
| 1y | 150.44% |
26.68
day range
28.32
9.57
52 week range
30.99
| Open | 27.18 | Prev Close | 27.15 | Low | 26.68 | High | 28.32 | Mkt Cap | 1.54B |
| Vol | 289.43K | Avg Vol | 675.35K | EPS | -2.78 | P/E | -10.13 | Forward P/E | -7.96 |
| Beta | -0.81 | Short Ratio | 10.80 | Inst. Own | 104.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 24.02 | 200-d Avg | 19.55 | 1yr Est | 31.46 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-11 | 2026-06 | -0.82 | N/A | N/A | N/A |
| 2026-05-11 | 2026-03 | -0.64 | -0.93 | -0.29 | -45.31% |
| 2026-03-26 | 2025-12 | -0.72 | -0.68 | 0.04 | 5.56% |
| 2025-11-10 | 2025-09 | -0.55 | -0.67 | -0.12 | -21.82% |
| 2025-08-12 | 2025-06 | -0.54 | -0.5 | 0.04 | 7.41% |
| 2025-05-13 | 2025-03 | -0.4 | -0.68 | -0.28 | -70.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-12 | Goldman Sachs | Upgrade | Neutral | Neutral |
| 2026-05-12 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-05-11 | Guggenheim | Upgrade | Buy | |
| 2026-03-31 | Goldman Sachs | Upgrade | Neutral | Neutral |
| 2026-03-31 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-03-31 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
Profile
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-15 | BIOCON LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-09-15 | FIL, LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-09-16 | FLYNN JAMES E | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-09-15 | FMR LLC | Unknown | 0.00 | Conversion of Exercise of derivative security |
| 2026-05-17 | MAZUMDAR CLAIRE | Chief Executive Officer | 362.15K | Conversion of Exercise of derivative security |
| 2024-09-15 | MAZUMDAR-SHAW KIRAN | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | RA Capital Management, L.P. | 7.26M | 209.77M | 11.04% |
| 2026-03-30 | T. Rowe Price Investment Management, Inc. | 6.61M | 190.97M | 10.05% |
| 2026-03-30 | Siren, L.L.C. | 5.80M | 167.76M | 8.83% |
| 2026-03-30 | Vestal Point Capital, LP | 5.43M | 156.84M | 8.26% |
| 2026-03-30 | Deep Track Capital, Lp | 4.06M | 117.45M | 6.18% |
| 2026-03-30 | Janus Henderson Group PLC | 3.34M | 96.54M | 5.08% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Small-Cap Stock Fund, Inc. | 2.18M | 63.07M | 3.32% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.37M | 39.65M | 2.09% |
| 2026-03-30 | T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 1.20M | 34.59M | 1.82% |
| 2026-03-30 | -Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 1.03M | 29.90M | 1.57% |
| 2026-05-30 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 944.90K | 27.32M | 1.44% |
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 781.32K | 22.59M | 1.19% |